NV-GUIDEWIRE
2.11.2021 13:57:08 CET | Business Wire | Press release
GUIDEWIRE CONNECTIONS– Guidewire (NYSE: GWRE) today unveiled Guidewire Live , a suite of analytics apps to equip insurers with real-time insights embedded in core systems across the insurance lifecycle. The announcement arrives with the launch of Dobson *, the latest release of Guidewire's market-leading cloud platform, at the company's Connections customer conference. Guidewire Live and Dobson will be featured in the keynote address at Connections which will be livestreamed today at 8.30am PT and available on-demand.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211102005525/en/
Guidewire Live's smart-loop analytics power the apps that provide insurers with curated intel from an array of high-value data sources. Live Apps are integrated with core systems and enable more accurate decision-making for claims managers, adjusters, underwriters, risk managers and actuaries. Support for open-source analytical models (Bring Your Own Model), new data visualizations, integration of HazardHub property risk insights with PolicyCenter, and greater internationalization capabilities are just a few of the latest innovations included in Guidewire Live.
“Traditionally, insurers have relied upon historical data to make decisions, but in today’s quickly changing market, this is no longer enough,” said Roger Arnemann, senior vice president and general manager, Analytics at Guidewire. “If insurers cannot react to what is happening now , they can’t succeed in the future. We are thrilled to introduce Guidewire Live as the industry’s first smart-loop analytics solution that enables insurers to outsmart, outpace, and outperform in a rapidly changing environment.”
In addition, new advances in the Dobson release of the Guidewire Cloud Platform (GWCP) deliver more cloud agility than ever before and empower developers to drive innovation.
- Guidewire GO**—The rapid expansion of our marketplace continues with GO Products, a new library of over 35 pre-packaged product definitions, so teams can launch new line of business products, fast.
- Cloud Integration Framework**—Reduce complexity across the insurance lifecycle with integrations that are easier to deploy and maintain with Integration Gateway, App Events and Cloud API.
- HazardHub—Now integrated with PolicyCenter, HazardHub provides risk insights for U.S. commercial property in seconds, delivering comprehensive risk data in one place.
- Blue-Green deployment—A new DevOps service that empowers developers to update configuration with zero downtime, enabling business continuity.
- Micro-BOP Solution—Deliver specialized experiences tailored to home-based businesses. Solutions include packaged product artifacts, configuration, and an expert team that help insurers go live with BOP coverage in as little as 12 weeks.
Guidewire was recently positioned as a Leader in the 2021 Gartner® Magic QuadrantTM for P&C Core Platforms, North America 1 for InsuranceSuite, marking its seventh consecutive year in the report. Guidewire was also named a Challenger for the fifth consecutive time in the same report for InsuranceNow. In addition, Guidewire has been positioned as a Leader in the 2021 Gartner Magic Quadrant for Non-Life Insurance Platforms, Europe .2 This is the fourth consecutive year InsuranceSuite has been recognized in the report.
Read more about Guidewire Live on our website or read our blog post .
To learn more about Dobson, visit our website .
*Guidewire Live and Dobson release will be generally available on November 12, 2021.
**Indicates product feature is available for Early Access customers only.
1 Gartner, Magic Quadrant for P&C Core Platforms, North America, Sham Gill and James Ingham, September 14, 2021
2 Gartner, Magic Quadrant for Non-Life-Insurance Platforms, Europe, Sham Gill and James Ingham, September 27, 2021
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER and MAGIC QUADRANT are registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.
About Guidewire
Guidewire is the platform P&C insurers trust to engage, innovate, and grow efficiently. We combine digital, core, analytics, and AI to deliver our platform as a cloud service. More than 450 insurers, from new ventures to the largest and most complex in the world, run on Guidewire.
As a partner to our customers, we continually evolve to enable their success. We are proud of our unparalleled implementation track record, with 1,000+ successful projects, supported by the largest R&D team and partner ecosystem in the industry. Our marketplace provides hundreds of applications that accelerate integration, localization, and innovation.
For more information, please visit www.guidewire.com and follow us on twitter: @Guidewire_PandC .
NOTE: All products mentioned in this announcement are Guidewire products. Not all products are available in every geography or to self-managed customers. Any unreleased services or features referenced in this or other press releases or public statements are not currently available and may not be delivered on time or at all. Customers who purchase Guidewire applications should make their purchase decisions based upon features that are currently available.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the future availability of the Dobson release, the general availability of features, programs, services, and tools related to Dobson mentioned in this release such as, smart loop analytics, blue-green deployment and micro-BOP solution and the early access features, programs, services and tools related to Dobson, such as Guidewire GO and Cloud Integration Framework. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “might,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Guidewire’s control. Guidewire’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in Guidewire’s most recent Forms 10-K and 10-Q filed with the Securities and Exchange Commission as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: quarterly and annual operating results may fluctuate more than expected; the impact of the COVID-19 pandemic on our employees and our business and the businesses of our customers, system integrator (“SI”) partners, and vendors; seasonal and other variations related to our customer agreements and related revenue recognition may cause significant fluctuations in our results of operations and cash flows; our reliance on sales to and renewals from a relatively small number of large customers for a substantial portion of our revenue; our ability to successfully manage any changes to our business model, including the transition of our products to cloud offerings and the costs related to cloud operations; our products or cloud-based services may experience data security breaches; we face intense competition in our market; our services revenue produces lower gross margins than our license, subscription and support revenue; our product development and sales cycles are lengthy and may be affected by factors outside of our control; changes in accounting guidance, such as revenue recognition, which have and may cause us to experience greater volatility in our quarterly and annual results; assertions by third parties that we violate their intellectual property rights could substantially harm our business; weakened global economic conditions may adversely affect the P&C insurance industry including the rate of information technology spending; general political or destabilizing events, including war, conflict or acts of terrorism; our ability to sell our products is highly dependent on the quality of our professional services and SI partners; the risk of losing key employees; the challenges of international operations, including changes in foreign exchange rates; and other risks and uncertainties. Past performance is not necessarily indicative of future results. The forward-looking statements included in this press release represent Guidewire’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. Guidewire undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Guidewire’s views as of any date subsequent to the date of this press release.
For information about Guidewire’s trademarks, visit https://www.guidewire.com/legal-notices .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005525/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom